-
公开(公告)号：US10391167B2
公开(公告)日：2019-08-27
申请号：US14917077
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Masahiro Fukasaka , Mitsuhiko Hori , Katsuyuki Okubo , Daisuke Asari , Arimichi Okazaki , Eiji Kiyotoh , Kyohei Matsushita
Abstract: The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. The mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.
-
公开(公告)号：US10206985B2
公开(公告)日：2019-02-19
申请号：US14166970
申请日：2014-01-29
Applicant: NITTO DENKO CORPORATION , OSAKA UNIVERSITY
Inventor： Daisuke Asari , Kyohei Matsushita , Arimichi Okazaki , Yoshiki Maeda , Katsuyuki Okubo , Mitsuhiko Hori , Haruo Sugiyama
Abstract: The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.
-
公开(公告)号：US09962439B2
公开(公告)日：2018-05-08
申请号：US14916807
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Kyohei Matsushita , Masahiro Fukasaka , Arimichi Okazaki , Eiji Kiyotoh , Katsuyuki Okubo , Daisuke Asari , Mitsuhiko Hori
CPC classification number: A61K39/39 , A61K9/0019 , A61K39/00 , A61K2039/55572
Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
-
14.发明授权公开(公告)号：US10925936B2
公开(公告)日：2021-02-23
申请号：US15507443
申请日：2015-09-02
Applicant: NITTO DENKO CORPORATION
Inventor： Takuya Shishido , Daisuke Asari , Mitsuhiko Hori
IPC: A61K39/00 , A61K31/047 , A61K31/05 , A61K31/085 , A61K31/355 , A61K31/4184 , A61K31/4192 , A61K31/663 , A61K31/675 , A61K31/685 , A61K33/00 , A61K31/42 , A61K31/192 , A61K31/12 , A61K9/70 , A61K38/00 , A61K31/19 , A61K31/4375 , A61K9/00 , A61K45/06 , A61K31/415 , A61K31/196 , A61K9/06 , A61K31/09 , A61K31/194 , A61K31/198 , A61K31/216 , A61K31/235 , A61K31/352 , A61K31/353 , A61K31/37 , A61K31/375 , A61K31/405 , A61K31/407 , A61K31/421 , A61K31/4745 , A61K31/5415 , A61K31/616 , A61K31/635 , A61K31/7048 , A61K33/04 , A61K38/10
Abstract: The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.
-
15.发明授权公开(公告)号：US10722570B2
公开(公告)日：2020-07-28
申请号：US15777441
申请日：2016-11-28
Applicant: NITTO DENKO CORPORATION
Inventor： Eiji Kiyotoh , Mitsuhiko Hori , Daisuke Asari , Katsuyuki Okubo , Takuya Shishido , Masahiro Fukasaka , Kyohei Matsushita
IPC: A61K39/00 , C07K14/00 , C12N9/90 , A61K38/00 , A61K39/108 , A61K39/145 , A61K47/26 , A61K9/19 , A61K47/18 , A61P31/16
Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an amino acid.
-
Patent Agency Ranking
公开(公告)号：US10195258B2
公开(公告)日：2019-02-05
申请号：US14166954
申请日：2014-01-29
Applicant: NITTO DENKO CORPORATION , OSAKA UNIVERSITY
Inventor： Yoshiki Maeda , Katsuyuki Okubo , Daisuke Asari , Arimichi Okazaki , Takuya Shishido , Mitsuhiko Hori , Haruo Sugiyama
Abstract: The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.
-
公开(公告)号：US10092642B2
公开(公告)日：2018-10-09
申请号：US14917084
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Masahiro Fukasaka , Mitsuhiko Hori , Katsuyuki Okubo , Daisuke Asari , Arimichi Okazaki , Eiji Kiyotoh , Kyohei Matsushita
IPC: A61K39/00 , A61K39/385 , A61K39/12 , A61K9/00 , A61K39/04 , A61K39/09 , A61K39/08 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/155 , A61K39/165 , A61K39/20 , A61K39/205 , A61K39/25 , A61K39/29 , C12N7/00
Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
-
公开(公告)号：US10071155B2
公开(公告)日：2018-09-11
申请号：US14916721
申请日：2014-10-02
Applicant: NITTO DENKO CORPORATION
Inventor： Eiji Kiyotoh , Mitsuhiko Hori , Katsuyuki Okubo , Daisuke Asari , Arimichi Okazaki , Masahiro Fukasaka , Kyohei Matsushita
IPC: A61K39/00 , A61K39/39 , A61K39/08 , A61K39/09 , A61K39/12 , A61K39/125 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/165 , A61K39/205 , A61K39/25
CPC classification number: A61K39/39 , A61K39/00 , A61K39/0011 , A61K39/08 , A61K39/092 , A61K39/12 , A61K39/125 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/165 , A61K39/205 , A61K39/25 , A61K2039/5252 , A61K2039/5254 , A61K2039/543 , A61K2039/55572 , A61K2039/575 , C12N2710/16734 , C12N2710/20034 , C12N2720/12334 , C12N2760/18434 , C12N2760/18734 , C12N2760/20134 , C12N2770/24134 , C12N2770/32434 , C12N2770/32634 , C12N2770/36234
Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
-
公开(公告)号：US10744197B2
公开(公告)日：2020-08-18
申请号：US15777396
申请日：2016-11-28
Applicant: NITTO DENKO CORPORATION
Inventor： Takuya Shishido , Daisuke Asari , Eiji Kiyotoh , Kyohei Matsushita , Wenjing Li , Masahiro Fukasaka , Katsuyuki Okubo , Mitsuhiko Hori
IPC: A61K39/00 , C07K14/00 , C12N9/90 , A61K38/00 , A61K39/108 , A61K39/145 , A61K47/26 , A61K47/36 , A61K47/38 , A61K9/19 , A61P31/16 , A61K47/18
Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.
-
公开(公告)号：US10456464B2
公开(公告)日：2019-10-29
申请号：US15501339
申请日：2015-08-04
Applicant: NITTO DENKO CORPORATION
Inventor： Takuya Shishido , Daisuke Asari , Kyohei Matsushita , Mitsuhiko Hori
IPC: A61K39/39 , A61K31/235 , A61K31/4465 , A61K31/4545 , A61K31/4709 , A61K31/5377 , A61K39/00
Abstract: The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.026 seconds)
